ModifiedPremera BluecrossPolicy N/A

Miscellaneous Pharmacologic Treatments of Psoriasis

Medical necessity and site-of-service criteria for various pharmacologic treatments for plaque psoriasis and generalized pustular psoriasis, including topical agents and Spevigo (spesolimab-sbzo); affects providers submitting medical benefit reviews and prior authorization requests.

Policy Summary

PayerPremera Bluecross

PolicyMiscellaneous Pharmacologic Treatments of Psoriasis

Policy CodePolicy N/A

Change TypeModified coverage and coding for spesolimab (Spevigo)

Effective DateJun. 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of weight (≥40 kg), GPPPGA score or flare history, and prior response when applicable.

SourceLink

POLICY UPDATE CHANGES

Added HCPCS code J1747 for Spevigo.

Updated coverage criteria for Spevigo SC clarifying use when not experiencing a flare, weight requirement (>=40 kg), and history of at least 2 moderate-to-severe GPP flares.

Updated criteria for Spevigo IV clarifying individual weighs at least 40 kg and re-authorization criteria for new flares after prior response.

Removed coverage criteria for Dovonex (calcipotriene) and Soriatane (acitretin) as products have been discontinued.

Clarified that Site of Service Medical Necessity criteria can apply to injection drugs and specified site-of-service age threshold of 13 years or older.

J1747HCPCS listed

≥12 yrsMinimum age

≥40 kgWeight requirement

2–3%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Topical agents — second-line and specific branded products

Covered when ALL of the following are met:

Age and diagnosis: Patient meets the specified minimum age for the requested topical agent (examples: Vtama/tapinarof ≥18 years; Zoryve cream ≥6 years; Zoryve foam ≥12 years) AND has chronic plaque psoriasis involving the agent-specific minimum body surface area (e.g., ≥3% for Vtama; ≥2% for many other agents).agent-specific age and BSA per policy

Prior topical therapy trials: History of an adequate trial and treatment failure or intolerance to at least 1 topical corticosteroid (e.g., betamethasone, clobetasol, mometasone) AND at least 1 vitamin D analogue (e.g., calcipotriene or calcitriol), unless contraindicated or not tolerated.failure to 1 corticosteroid and 1 vitamin D analogue

Agent-specific prior-product requirement (when applicable): For combination or branded products that combine agents (for example, Duobrii), documentation of trial and inadequate response or intolerance to the concurrent generic components (e.g., concurrent generic topical halobetasol and generic topical tazarotene) is required when specified by the product-specific criteria.

Prescriber: Medication is being prescribed by or in consultation with a dermatologist.

Spevigo IV — GPP flare (medically necessary)

Medically necessary when ALL of the following are met:

Age and weight: Individual is aged 12 years or older AND weighs at least 40 kg.age >=12; weight >=40 kg

Current episode: Is experiencing a generalized pustular psoriasis (GPP) flare AND has documentation of a Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) total score of at least 3 (moderate).GPPPGA >=3

Dose for flare: Dose prescribed is 900 mg given as an IV infusion (an additional 900 mg may be administered one week after the initial dose).

Prescriber:

Spevigo SC — GPP maintenance or prevention (medically necessary)

Medically necessary when ALL of the following are met:

Age and weight: Individual is aged 12 years or older AND weighs at least 40 kg.age >=12; weight >=40 kg

Flare history: Has a history of at least 2 GPP flares of moderate-to-severe intensity (for example, prior GPPPGA total score ≥3).>=2 prior moderate-to-severe flares

Current status: Member is not currently experiencing an acute GPP flare (maintenance/prevention use).

Dose for maintenance: Prescribed subcutaneous loading dose of 600 mg followed by 300 mg subcutaneously 4 weeks later and every 4 weeks thereafter (600 mg LD → 300 mg q4w).

Not medically necessary / Investigational

Policy stances — uses considered not medically necessary or investigational:

Not medically necessary uses: All other uses of the drugs listed in this policy that are not specifically enumerated as medically necessary (including uses for approved conditions not listed) are considered not medically necessary.

Investigational uses: Use of the agents in combination with each other or for conditions not outlined in this policy is considered investigational. Use of spesolimab for palmoplantar pustulosis (PPP) is not supported by positive primary trial outcomes and is not an approved indication; such use is considered investigational or not medically necessary as detailed in the policy.

Spevigo coverage criteria

Covered when ALL of the following are met:

Spevigo SC maintenance: Member has a diagnosis of generalized pustular psoriasis (GPP) with a history of at least 2 GPP flares of moderate-to-severe intensity; member is not currently experiencing a flare; member weighs at least 40 kg; prescriber intends a subcutaneous loading dose of 600 mg followed by 300 mg every 4 weeks.weight >=40 kg

The recommended SC maintenance regimen is 600 mg LD then 300 mg q4w; other studied regimens (e.g., 600 mg LD → 300 mg q12w or 300 mg LD → 150 mg q12w) were studied but are not approved.

Spevigo IV for acute flare: Member is experiencing a GPP flare (as defined in trials by GPPPGA pustulation subscore ≥2 with appropriate increase in total score); member weighs at least 40 kg; IV administration plan of 900 mg IV (with an optional additional 900 mg one week later) is documented; for re-authorization, member previously received Spevigo IV for a prior flare, achieved clinical response, and is now experiencing a new flare.weight >=40 kg

Re-authorization for IV dosing requires documentation of prior response to IV spesolimab and a new GPP flare.

All other uses of the drugs listed in this policy that are not specifically outlined in the coverage criteria are considered investigational. This includes use of the agents in combinations not described here or for clinical indications not enumerated in the policy.

The manufacturer is not currently seeking FDA approval for treatment of palmoplantar pustulosis (PPP). A randomized Phase 2a trial did not demonstrate a statistically significant benefit for spesolimab versus placebo on the trial’s primary outcome (PPPASI-50 at Week 16), and the study was considered exploratory without formal statistical testing. Because PPP is not an approved indication and the manufacturer is not pursuing approval, use of spesolimab for PPP is not supported as an approved indication.

All other uses of the drugs for approved conditions listed in this policy that are not specifically enumerated as covered are considered not medically necessary. Providers should not expect coverage for indications or combinations outside those detailed in the policy unless explicitly approved.

Use of spesolimab for palmoplantar pustulosis (PPP) is not supported by the available clinical trial evidence and is not an FDA‑approved indication. In a 16‑week Phase 2a trial there was no meaningful difference versus placebo on the primary endpoint (PPPASI‑50 at Week 16), and the manufacturer is not pursuing FDA approval for PPP; therefore spesolimab for PPP is not considered a supported indication under this policy.

Coding

HCPCSHCPCS

J1747

Injection, spesolimab-sbzo (Spevigo), 1 mg

Spevigo HCPCSHCPCSCovered

J1747

Injection, spesolimab-sbzo, 1 mg

GPPPGA total score

GPPPGA total score>= 3 (clinician-rated scale 0–4; >=3 = moderate-to-severe)

Scale range0 = clear to 4 = severe

Use in flare criteriaRequired documentation of total GPPPGA >=3 for Spevigo IV flare eligibility

Body surface area (BSA) thresholds for topical agents

BSA threshold (general topical agents)>= 2% for many topical agents (e.g., Zoryve cream/foam requires >=2% depending on age),

Vtama (tapinarof) specific BSA>= 3% for Vtama (tapinarof) cream; age >= 18 years also required

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Spevigo (spesolimab-sbzo). Both IV (HCPCS J1747) and SC routes are subject to prior authorization review. Subcutaneous administration may be managed under the medical or pharmacy benefit depending on member plan; providers should submit the appropriate prior authorization request and supporting clinical documentation to determine benefit and medical necessity.

Spevigo IV — HCPCS J1747; 900 mg IV dosing per policy
Spevigo SC — managed via medical or pharmacy benefit per plan
Prior authorization must include documentation of diagnosis, weight (≥ 40 kg when required), and GPP disease activity

Denial Risk

Site-of-Service Denial Risk

Site-of-service medical necessity review applies to IV and injectable therapies and may render certain infusion or injectable service locations not medically necessary when site-of-service criteria are not met. Spevigo IV is specifically reviewed for appropriate site-of-service administration; ensure the chosen administration setting meets SOS criteria or the claim may be denied as not medically necessary.

Background

Psoriasis is a chronic inflammatory skin disease characterized by erythematous, scaly plaques. Standard management begins with topical therapies (typically topical corticosteroids, often combined with vitamin D analogues) because they are easy to administer and appropriate for limited disease. For individuals with disease that is widespread or refractory to topicals, escalation to phototherapy, systemic non-biologic agents, or biologic therapies is considered. Pustular forms of disease (including generalized pustular psoriasis) are distinct clinical variants that may require IV or systemic biologic therapy and are managed according to severity and flare history, as reflected in the specific coverage criteria for Spevigo (spesolimab‑sbzo).

Definitions

Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA)

GPPPGA scale descriptionClinician-rated scale ranging from 0 (clear) to 4 (severe)

Eligibility threshold for Spevigo flare>= 3 (moderate-to-severe) required to document current GPP flare for IV treatment

Referenced useGPPPGA total score used in trial definitions and required documentation for medical necessity

Generalized pustular psoriasis (GPP)

DefinitionGeneralized pustular psoriasis (GPP): sterile, visible pustules on non-acral skin; may occur with or without systemic inflammation

Clinical course and severityGPP is a rare, relapsing/remitting multisystem disease that can be life-threatening with systemic symptoms and high infection risk during flares